Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Alector, Inc. Common Stock

ALEC

Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.

Last trade $2.56
Day change -$0.01 (-0.39%)
Day range $2.49 – $2.59
Volume 671,851
Market cap $383M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$382.61M
Price / earnings
9.3×
Price / book
3.28×
Price / sales
2.21×
EV / sales
1.77×
EV / EBITDA
7.83×

Profitability

Earnings per share
$0.28
Return on assets
24.82%
Return on equity
35.29%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.1×
Quick ratio
4.1×
Cash ratio
2.13×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$150.02M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ALEC, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$162.87M$3.32M$1.05M$6.24M$3.26M$7.87M$3.67M$54.24M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$162.87M$3.32M$1.05M$6.24M$3.26M$7.87M$3.67M$54.24M
Selling, general and administrative$8.99M$8.25M$8.11M$13.34M$11.52M$14.4M$14.73M$15.03M
Research and development$30.03M$19.46M$17.86M$32.46M$29.35M$27.61M$33.64M$46.46M
Total operating expenses$39.03M$27.71M$25.97M$45.8M$40.87M$42.01M$48.37M$61.49M
Operating income$123.84M-$24.39M-$24.92M-$39.57M-$37.61M-$34.14M-$44.7M-$7.25M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$124.66M-$22.86M-$22.93M-$37.1M-$34.67M-$30.52M-$40.47M-$2.03M
Income taxes$60K$130K$0$168K$0$0$0$48K
Net income$124.6M-$22.99M-$22.93M-$37.27M-$34.67M-$30.52M-$40.47M-$2.07M
Net income attributable to common shareholders$124.6M-$22.99M-$23.2M-$37.27M-$34.67M-$30.52M-$40.54M-$2.07M
EBITDA$124.82M-$23.34M-$23.84M-$38.4M-$36.37M-$31.81M-$43.71M-$6.01M
Basic earnings per share$1.11-$0.21-$0.21-$0.34-$0.34-$0.30-$0.41-$0.02
Diluted earnings per share$1.11-$0.21-$0.21-$0.34-$0.34-$0.30-$0.41-$0.02

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

IQVIA Stock Jumps 59% in 6 Months: Here's What You Should Know

IQVIA Holdings (IQV) reported solid Q3 2026 results with R&D Solutions revenues up 8.7% year-over-year and net new bookings growing 15%, while Commercial Solutions revenues grew 6.9%. The company's deployment of 415 AI agents has improved operational efficiency, with adjusted EBITDA rising 8.7% and margins expanding by 20 basis points. Despite strong performance, IQV holds a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

Earnings Estimates Rising for Alector (ALEC): Will It Gain?

Alector (ALEC) has attracted investor interest due to solid improvements in earnings estimates, with consensus estimates rising significantly for both the current quarter and full year. The company currently holds a Zacks Rank #2 (Buy) rating, supported by upward estimate revisions from analysts. The stock has gained 35.3% over the past four weeks, with potential for further upside.

GlobeNewswire Inc.

Dementia Market Insight, Epidemiology, and Forecasts, 2022-2025 & 2026-2034

The dementia therapeutics market is experiencing significant growth driven by emerging disease-modifying treatments for early-stage Alzheimer's and promising therapies for other dementia subtypes. With approximately 55 million people globally affected by dementia, the market is shifting toward proactive intervention with drugs like LEQEMBI and KISUNLA leading the way, while the pipeline shows promise with novel agents targeting diverse symptoms and unmet needs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.